New track in the field of tumor treatment: oncolytic bacteri

本篇文章7685字，读完约19分钟

Every progress and innovation in life science may affect and change the course of human destiny, especially in the face of cancer which is highly threatening to human health. Every research and invention related to new medical technology carries infinite hopes and expectations of all mankind.

The era of cancer immunotherapy is on the rise

With the emergence of more and more new therapies and technologies, such as antibody therapy, cell therapy, vaccines that trigger antigen-specific immune responses in tumors and oncolytic carriers, the field of cancer therapy has opened a great era of immunotherapy.

With the joint efforts of many scientific and technological researchers, biotechnology companies and the entire biomedical industry, the new discovery of tumor immunotherapy in recent years has brought new hope to cancer patients all over the world and also proves the firm determination of human beings to cure cancer.

Antibody therapy, CAR T cell therapy, and oncolytic viruses have been developed, and the field of tumor immunotherapy continues to innovate. In this industry background,YB1, as the most cutting-edge technology achievement in the field of tumor immunotherapy, has been successfully published. A new subpision track -- oncolytic bacterial immunotherapy will emerge in the field of tumor immunotherapy, which will open up a new path for human to conquer cancer.

YB1 makes it possible to treat cancer with bacteria

A hundred years ago, scientists had been exploring and researching the treatment of cancer by bacteria, but few achievements have been made. At present, the world's first successfully developed oncolytic bacterial vector is YB1, a genetically programmed strain of Salmonella typhimurium invented by HKND YB1 PHARMACEUTUCAL LIMITED. 

HKND YB1 PHARMACEUTUCAL LIMITED. is a biotechnology company focusing on the development of innovative drugs in the field of tumor targeted therapy and is committed to providing revolutionary cancer immunotherapy solutions to the world. We have a world leading platform for oncolytic bacteria drug delivery based on synthetic biology with independent intellectual property rights. Relying on the core technology product YB1, a set of YB1 oncolytic bacterial immunotherapy technology with high safety and effectiveness has been formed.

YB1 is the world's first oncolytic bacterial carrier with powerful drug carrying capacity, which can efficiently deliver antibodies, mRNA, protein drugs, etc. By accurately targeting the hypoxic region inside the tumor and replicating in the tumor, increasing the concentration of YB1 carrier at the target location of solid tumor and releasing the carried therapeutic drugs, so as to inhibit tumor growth and cause tumor dissolution. At the same time, YB1 can eliminate tumor metastasis, which has great potential in clinical application.

As the application of YB1 continues to advance, using bacteria to treat cancer is no longer  a distant legend. In the process of research of YB1, many technical difficulties were overcame.YB1 condensed the painstaking efforts of the R&D team for more than 10 years.

How does YB1 achieve immune activation?

As a pioneering emerging tumor immunotherapy, how does YB1 technology activate human immunogenicity?

From the perspective of the anti-tumor mechanism of YB1, its immune activation could be pided into several steps:

First, YB1 is injected into blood and quickly activate the immune system, including macrophages which can secrete tumor necrosis factor (TNFa). TNFa could impact on tumor blood vessels and result in damage to the tumor inner loop system. 

Secondly, YB1 also activates NK cells. NK cells (natural killer cells) are important immune cells which are not only related to anti-tumor, antiviral infection and immune regulation, but also involved in the occurrence of hypersensitivity and autoimmune diseases in some cases to recognize target cells and killing agents. YB1 activates NK cells and induces the secretion of IFN-γ. IFN-γ (INTERFER y) which has antiviral, anti-tumor and immunoregulatory effects and can regulate the expression of 30 genes to produce a variety of cellular responses and destroy the metastasized tumor cells.

Finally, if YB1 carries a tumor antigen, it also triggers the body's acquired immune system to form antibodies against the tumor antigen.

How does YB1 carry and release drugs?

Among all kinds of oncolytic vector products, YB1 has outstanding drug carrying ability. From the perspective of technology, YB1 can carry antibodies, protein drugs, mRNA vaccines and other drugs by plasmid and genome.

There are three release modes of YB1 according to the different drugs carried. First,YB1 is combined with the drug and directly released into the tumor. Second, YB1 carries eukaryotic plasmids and delivers related genes to cancer cells or adjacent cells through presentation mode, and then performs drug synthesis; Third, YB1 can bind antibodies or other protein molecules in the head to form a drug structure similar to ADCs. The above multiple modes of drug delivery and release can greatly enhance the specificity of YB1 to tumor.

YB1 is administered in a flexible manner

At the clinical level, the market is concerned about the delivery of this novel tumor immunotherapy product. In the case of YB1, the administration method is very flexible which can be given either simply by intravenous IV injection or intravenously.

In the case of IV injections,YB1 is distributed in the bloodstream. The research team of HKND YB1 PHARMACEUTUCAL LIMITED.  observed in the imaging system that YB1 entered the tumor circulation system after the caudal vein injection 2 minutes.

It is worth noting that YB1 does not migrate directly to the hypoxic region. If YB1 is always free in the circulatory system, it will be cleared by immune cells and high oxygen concentration in the blood will also cause YB1 death. By activating tumor necrosis factor TNFa secreted by macrophages, YB1 causes damage to vascular endothelial cells in the tumor and then causes local coagulation in the tumor to form hypoxic zone, so as to realize the colonization of YB1 in the tumor. YB1 replicates and proliferates in this region and releases antitumor drugs, exerting its oncolytic effect.

Enrich products pipelines

YB1 is the world's first oncolytic bacteria constructed with the concept of synthetic biology, and its world-first tumor hypoxic specific targeting technology has also been granted by the patent of oxygen-regulated oncolytic bacteria from the United States, the European Union and China.

At present, HKND YB1 PHARMACEUTUCAL LIMITED.  has laid out a number of product pipelines for  YB1 technology. In the field of tumor immunotherapy, YB1 can carry a variety of drugs and is suitable for sarcoma, melanoma, PDL1 positive melanoma and other solid tumors, etc. In addition to being able to carry a variety of warhead drugs, YB1 application also has a broad and powerful technology extension which is applicated to ADC and a variety of thrombosis therapy.

At present, HKND YB1 PHARMACEUTUCAL LIMITED. is promoting the development of several YB1 pipelines and the most advanced pipeline is yB1-TOX which has completed pre-clinical trials. The next step is to launch IND clinical application, then promote the clinical trials and IPO process as planned.

As the star product of the race track of oncolytic bacteria,YB1 has attracted wide attention in the market and major pharmaceutical companies have also started to lay out the product pipeline of oncolytic bacteria. In the foreseeable future, the global cancer immunotherapy field will be the home field of oncolytic bacteria and the development prospect of YB1 is worth looking forward.